Mylan Pharmaceuticals, the subsidiary of Mylan, has introduced Fenofibrate tablets, 48 mg and 145 mg.
The company has received the final approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Fenofibrate, which is the generic version of Abbvie Tricor Tablets.
Fenofibrate tablets are shown to reduce elevated low-density lipoprotein cholesterol (LDL-C), total cholesterol (Total-C), Triglycerides and apolipoprotein B (Apo B) in the diet, and to increase high-density lipoprotein cholesterol (HDL-C) in adult patients with primary hypercholesterolemia or mixed dyslipidemia.
Fenofibrate tablets also are indicated to treat adult patients with severe hypertriglyceridemia.
According to IMS Health, Fenofibrate tablets, 48 mg and 145 mg, had US sales of approximately $1.2bn for the 12 months ending 31 March 2013.
